natgillin/translations-raw huggingface dataset:
Ziagen is used in combination with other antiviral medicines to treat patients who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
Ziagen se koristi u kombinaciji s drugim antiviroticima za liječenje bolesnika zaraženih virusom humane imunodeficijencije tipa (HIV), virusom koji uzrokuje sindrom stečene imunodeficijencije (AIDS).
Why has Ziagen been approved?
Zašto je Ziagen odobren?
Patients receiving Ziagen also had increases in their CD4 cell counts.
U bolesnika koji su primali Ziagen također je zabilježeno povećanje broja CD4 stanica.
Ziagen has been studied in six main studies including 1,843 HIV-infected adults (aged 18 years and over).
Ziagen je ispitan u šest glavnih ispitivanja kojima je obuhvaćeno 1.843 odraslih osoba zaraženih HIVom (u dobi od 18 godina ili starijih).
The active substance in Ziagen, abacavir, is a nucleoside reverse transcriptase inhibitor (NRTI).
Djelatna tvar lijeka Ziagen, abakavir, jest nenukleozidni inhibitor povratne transkriptaze (NNRTI).
Patients who take Ziagen will also receive an alert card summarising the key safety information on hypersensitivity with the medicine.
Bolesnici koji uzimaju Ziagen također će primiti karticu upozorenja koja sadrži sažetak ključnih informacija za sigurnu primjenu vezanih uz preosjetljivost na ovaj lijek.
What is the risk associated with Ziagen?
Koji su rizici povezani s lijekom Ziagen?
Ziagen should be prescribed by a doctor who has experience in the management of HIV infection.
Terapiju lijekom Ziagen mora propisati liječnik s iskustvom u liječenju infekcije HIV-om.
Ziagen is a medicine that contains the active substance abacavir.
Ziagen je lijek koji sadrži djelatnu tvar abakavir.
One study compared the effects of Ziagen taken once and twice a day, in combination with lamivudine and efavirenz (other antiviral medicines) in 784 patients.
U jednom se ispitivanju usporedilo djelovanje lijeka Ziagen koji se uzimao dvaput na dan u kombinaciji s lamvudinom i efavirenzom (drugim antiviroticima) u 784 bolesnika.
In all of the studies, Ziagen caused a decrease in viral loads, particularly when taken with other antiviral medicines.
Ziagen je uzrokovao smanjenje virusnog opterećenja, posebice ako se uzimao s drugim antiviroticima.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ziagen, including the appropriate precautions to be followed by healthcare professionals and patients.
Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Ziagen nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
Ziagen's effects were compared with other antiviral medicines, placebo (a dummy treatment) or no treatment.
Djelovanje Ziagena uspoređeno je s drugim antiviroticima, placebom (prividnim liječenjem) ili bez liječenja.
What is Ziagen used for?
Za što se Ziagen koristi?
Ziagen was taken alone, or added to the combination of lamivudine and zidovudine (other antiviral medicines) or the patients' existing HIV treatment.
Ziagen je uziman kao monoterapija ili u kombinaciji s lamivudinom i zidovudinom (drugim antivirotikom) ili s postojećom terapijom protiv HIV-a.
For the full list of all side effects and restrictions with Ziagen, see the package leaflet.
Potpuni popis nuspojava i ograničenja zabilježenih pri primjeni lijeka Ziagen potražite u uputi o lijeku.
Once- and twice-daily Ziagen had similar effects on viral load.
Primjena lijeka Ziagen jednom na dan ili dvaput na dan imala je slično djelovanje na virusno opterećenje.
What benefit has Ziagen shown during the studies?
Koje su koristi lijeka Ziagen utvrđene u ispitivanjima?
How is Ziagen used?
Kako se Ziagen koristi?
How does Ziagen work?
Kako djeluje Ziagen?
How has Ziagen been studied?
Kako je Ziagen ispitivan?
Cmax occurs approximately 30 to 60 minutes after
Cmax postiže se otprilike 30 do 60 minuta nakon doziranja.
Merckle GmbH Ludwig-Merckle-Strasse 3 89143 Blaubeuren Germany
Merckle GmbH Ludwig-Merckle-Straße 3 89143 Blaubeuren
• If you are allergic to clopidogrel or any of the other ingredients of this medicine (listed in
• ako ste alergični na klopidogrel ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.)
In addition, clinical tolerance was good in
Osim toga, klinička podnošljivost bila je dobra u svih bolesnika.
Some other medicines may influence the use of Clopidogrel ratiopharm or vice versa.
Neki lijekovi mogu utjecati na djelovanje lijeka Klopidogrel ratiopharm i obratno.
Since the CAPRIE trial was not powered to evaluate efficacy of individual subgroups, it is not clear whether the differences in relative risk reduction across qualifying conditions are real, or a result of
Kako kliničko ispitivanje CAPRIE nije za cilj imalo procijeniti djelotvornost u pojedinačnim podskupinama, nije jasno jesu li razlike relativnog smanjenja rizika unutar podskupina stvarne ili su slučajan rezultat.
Contents of the pack and other information What Clopidogrel ratiopharm contains
Sadržaj pakiranja i druge informacije Što Klopidogrel ratiopharm sadrži
Their frequency is defined using the following conventions: common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
<1/100); rijetke (≥1/10 000, <1/1000); vrlo rijetke (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
For any information about this medicine, please contact the local representative of the Marketing
Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje lijeka promet:
What Clopidogrel ratiopharm is and what it is used for What you need to know before you take Clopidogrel ratiopharm
Što je Klopidogrel ratiopharm i za što se koristi Što morate znati prije nego počnete uzimati Klopidogrel ratiopharm
Clopidogrel should not be used in children because of efficacy concerns (see section 5.1).
Klopidogrel se ne smije primjenjivati u djece zbog razloga djelotvornosti (vidjeti dio 5.1).
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 2 ‘Warnings and precautions').
Ukoliko ste ipak zabrinuti zbog krvarenja, odmah obavijestite svog liječnika (pogledajte dio 2 „Upozorenja i mjere opreza“).
* Information related to clopidogrel with frequency “not known”
* Podaci se odnose na klopidogrel s učestalosti „nepoznato“.
You should take Clopidogrel ratiopharm for as long as your doctor continues to prescribe it.
Klopidogrel ratiopharm trebate uzimati onoliko dugo koliko Vam ga liječnik propisuje.
What you need to know before you take Clopidogrel ratiopharm
Što morate znati prije nego počnete uzimati Klopidogrel ratiopharm
The binding is non-saturable in vitro over a wide concentration
Vezanje nije zasićeno in vitro u širokom rasponu koncentracija.
Apart from the specific medicinal products interaction information described above, interaction studies with clopidogrel and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed.
Osim prethodno opisanih interakcija sa specifičnim lijekovima, nisu provedena ispitivanja interakcija klopidogrela s nekim lijekovima koji se obično propisuju bolesnicima s aterotrombotskom bolesti.
In view of the lack of data, clopidogrel cannot be recommended during the first 7 days after acute
S obzirom da nema podataka, klopidogrel se ne preporučuje tijekom prvih 7 dana nakon akutnog ishemijskog moždanog udara.
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects').
• Također, odmah obavijestite svog liječnika ako se pojavi medicinsko stanje (koje se naziva trombotična trombocitopenična purpura ili TTP) sa simptomima koji uključuju vrućicu i potkožne modrice koji se mogu pojaviti kao crvene točkice, sa ili bez neobjašnjivog teškog umora, zbunjenosti i žute boje kože ili očiju (žutica) (pogledajte dio 4. „Moguće nuspojave“).
Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji, boci ili blisteru iza oznake „EXP“.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of
Nuspojave možete prijaviti izravno putem nacionalnog sustava za prijavu nuspojava: navedenog u Dodatku V . Prijavljivanjem nuspojava možete pridonijeti u procjeni sigurnosti ovog lijeka.
Heparin: in a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.
Heparin: u jednoj kliničkoj studiji provedenoj na zdravim ispitanicima, primjena klopidogrela nije zahtjevala promjenu doze heparina, niti je mijenjala učinak heparina na koagulaciju.
What Clopidogrel ratiopharm is and what it is used for
Što je Klopidogrel ratiopharm i za što ste koristi
In a relative bioavailability study in adults, the constituted solution of clopidogrel showed a similar extent and slightly higher rate of absorption of the main circulating (inactive) metabolite compared to the
U relativnoj studiji bioraspoloživosti lijeka u odraslih, konstituirana otopina klopidogrela pokazala je sličan raspon i neznatno veću brzinu apsorpcije glavnog cirkulirajućeg (neaktivnog) metabolita, u usporedbi s tabletom.
As a precautionary measure, breast-feeding should not be continued during treatment with clopidogrel.
Kao mjera opreza, treba prestati s dojenjem za vrijeme liječenja lijekom
Clopidogrel ratiopharm contains the active ingredient Clopidogrel which belongs to a group of medicines called antiplatelet medicinal products.
Klopidogrel ratiopharm sadrži klopidogrel i pripada skupini lijekova koji se nazivaju antitrombocitni lijekovi.
Clopidogrel ratiopharm is unlikely to affect your ability to drive or to use machines.
Klopidogrel ratiopharm ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
Platelets (so-called thrombocytes) are very small structures, which clump together during blood clotting.
Trombociti su vrlo mala krvna tjelešca, tzv. krvne pločice, koje se nakupljaju tijekom zgrušavanja krvi.
While you are taking Clopidogrel ratiopharm:
Dok uzimate Klopidogrel ratiopharm:
Clopidogrel ratiopharm is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
Klopidogrel ratiopharm uzimaju odrasli za sprječavanje stvaranja krvnih ugrušaka (tromba) u otvrdnutim krvnim žilama (arterijama), a taj poremećaj zove se aterotromboza i može dovesti do aterotrombotičkih događaja (kao što su moždani udar, srčani udar ili smrt).
Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting); swelling in the mouth; blisters of the skin; skin allergy; sore mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain;
žutica; jaka bol u trbuhu s ili bez bolova u leđima; vrućica, teškoće pri disanju, ponekad povezane s kašljem; generalizirane alergijske reakcije (primjerice, sveukupni osjećaj vrućine s iznenadnom općom nelagodom do nesvjestice); oticanje u ustima; mjehurići na koži; kožne alergijske reakcije; upala u usnoj šupljini (stomatitis); pad krvnoga tlaka; zbunjenost; halucinacije; bol u zglobovima; bol u mišićima; poremećaj okusa ili gubitak osjeta okusa hrane.
However, the marketing authorisation holder shall submit periodic safety update reports for this medicinal product if the product is included in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Zahtjevi za podnošenje PSUR-eva za ovaj lijek definirani su u referentnom popisu datuma EU (EURD popis) predviđenom člankom 107.c stavkom 7. Direktive 2001/83/EZ i svim sljedećim ažuriranim verzijama objavljenima na europskom internetskom portalu za lijekove.
Mean peak plasma levels of unchanged clopidogrel (approximately 2.2 - 2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing.
Srednje vršne razine nepromijenjenog klopidogrela u plazmi (oko 2,2 - 2,5 ng/ml nakon jednokratne oralne doze od 75 mg), postižu se otprilike 45 minuta nakon uzimanja lijeka.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system
Od zdravstvenih radnika se traži da prijave svaku sumnju na nuspojavu lijeka putem nacionalnog sustava prijave nuspojava: navedenog u Dodatku V.
If you are breastfeeding or planning to breastfeed, talk to your doctor before taking this medicine.
Ako dojite ili planirate dojiti, obratite se svom liječniku prije uzimanja ovog lijeka.
If you forget to take Clopidogrel ratiopharm
Ako ste zaboravili uzeti Klopidogrel ratiopharm
Although the administration of clopidogrel 75 mg/day did not modify the pharmacokinetics of S-warfarin or International Normalised Ratio (INR) in patients receiving long-term warfarin therapy, coadministration of clopidogrel with warfarin increases the risk of bleeding because of independent
Iako primjena klopidogrela u dozi od 75 mg na dan nije utjecala na farmakokinetiku S-varfarina ili INR (International Normalised Ratio) u bolesnika koji primaju dugotrajnu terapiju varfarinom, istodobna primjena klopidogrela s varfarinom povećava rizik od krvarenja zbog nezavisnih učinaka na hemostazu.
In CURE, CLARITY, ACTIVE-A and one of the cohort studies (Trenk), no increased event rate was
U studijama CURE, CLARITY, ACTIVE-A i jednoj od kohortnih studija (Trenk), nije uočena povećana stopa događaja temeljena na metabolizatorskom statusu.
In addition, IPA was 32% (24 hours) and 61% (Day 5), which were greater than in the poor metabolisers receiving the 300 mg/75 mg regimen, and were similar to the other CYP2C19 metaboliser groups receiving the 300 mg/75 mg regimen.
vrijednost IPA iznosila je 32% (24 sata) i 61% (dan 5), što je više nego u slabih metabolizatora koji su primali doze od 300 mg/75 mg i slično je ostalim skupinama CYP2C19 metabolizatora koje su primale doze od 300 mg/75 mg.
Consistent with the above results, in a meta-analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers.
U skladu s gore navedenim rezultatima, metaanaliza koja je uključivala 6 studija sa 335 osoba liječenih klopidogrelom u stanju dinamičke ravnoteže, pokazala je da je izloženost aktivnom metabolitu smanjena za 28% za umjerene metabolizatore te 72% za slabe metabolizatore, dok je inhibicija agregacije trombocita (5 μM ADP) smanjena s razlikama za vrijednosti IPA-a od 5,9%, odnosno 21,4%, u usporedbi s brzim metabolizatorima.
In a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported.
U manjem broju slučajeva, također su zabilježena krvarenja u oku, glavi, trbušnoj šupljini, plućima ili zglobovima.
If you become pregnant while taking Clopidogrel ratiopharm, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
Klopidogrel ratiopharm, odmah se posavjetujte s liječnikom jer nije preporučeno uzimati klopidogrel za vrijeme trudnoće.
• Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial
• odraslih bolesnika koji su pretrpjeli infarkt miokarda (u rasponu od nekoliko do najviše 35 dana), ishemijski moždani udar (u rasponu od 7 dana do najviše 6 mjeseci) ili imaju utvrđenu bolest perifernih arterija.
The active substance is clopidogrel.
• Djelatna tvar je klopidogrel.
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel ratiopharm.
Ako mislite da se bilo što od navedenog odnosi na Vas, ili niste sigurni, obratite se svom liječniku prije uzimanja lijeka Klopidogrel ratiopharm.
Bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma (unusual bleeding or bruising under the skin), nose bleed, blood in the urine.
Krvarenje se može pojaviti u obliku krvarenja u želucu ili crijevima, modrica, hematoma (neuobičajeno krvarenje ili modrice ispod kože),
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p=0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to
U analizi podskupina sačinjenih prema stanju (infarkt miokarda, ishemijski moždani udar, BPA) najveću su korist od liječenja (postignuta statistička značajnost pri p = 0,003) imali bolesnici s bolešću perifernih arterija (BPA), posebno oni koji su u anamnezi imali infarkt miokarda (RRR = 23,7%; CI:
Other medicines and Clopidogrel ratiopharm Tell your doctor or pharmacist if you are taking/using, have recently taken/used or might take/use any
Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKO PAKIRANJE - BOCE
You have a condition of hardening of arteries (also known as atherosclerosis), and You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease (disturbed blood flow in arms or legs caused by vascular
- imate otvrdnuće arterija (koje se još zove ateroskleroza) te - ste već imali srčani udar, moždani udar ili imate stanje koje se zove bolest perifernih arterija, ili
No effect on hepatic metabolising enzymes was observed in humans receiving clopidogrel at the
Učinak na jetrene metaboličke enzime nije primijećen u ljudi koji su primali terapijske doze klopidogrela.
UAB "Sicor Biotech" Eesti filiaal Tel: +372 661 0801
UAB Teva Baltics Eesti filiaal Tel: +372 661 0801
Method of administration For oral use
UPUTE ZA UPORABU
-Very rare side effects (may affect up to 1 in 10,000 people):
Vrlo rijetke nuspojave (mogu se javiti u manje od 1 na 10 000 osoba):
The dose of 0.2 mg/kg achieved the mean percent inhibition of 49.3% (5 µM ADP-induced platelet aggregation) which was comparable to that of adults taking
S dozom od 0,2 mg/kg postignut je prosječni postotak inhibicije od 49,3% (5 µM
EU/1/09/554/001 - 14 film-coated tablets EU/1/09/554/002 - 28 film-coated tablets EU/1/09/554/003 - 30 film-coated tablets EU/1/09/554/004 - 50 film-coated tablets EU/1/09/554/005 - 84 film-coated tablets EU/1/09/554/006 - 90 film-coated tablets EU/1/09/554/007 - 100 film-coated tablets EU/1/09/554/008 - 7 film-coated tablets
EU/1/14/975/001 14x1 filmom obloženih tableta EU/1/14/975/002 28x1 filmom obloženih tableta EU/1/14/975/003 30x1 filmom obloženih tableta EU/1/14/975/004 50x1 filmom obloženih tableta EU/1/14/975/005 84x1 filmom obloženih tableta EU/1/14/975/006 90x1 filmom obloženih tableta EU/1/14/975/007 100x1 filmom obloženih tableta
If you stop taking Clopidogrel ratiopharm Do not stop the treatment unless your doctor tells you so.
Ne prekidajte liječenje osim ako Vam to ne savjetuje liječnik.
Patients should be evaluated for history of hypersensitivity to another thienopyridine (such as ticlopidine, prasugrel) since allergic cross-reactivity among thienopyridines has been reported (see section 4.8).
Kod bolesnika treba procijeniti prethodnu preosjetljivost na tienopiridine u povijesti bolesti (kao što su klopidogrel, tiklopidin, prasugrel) budući da je zabilježena ukrižena reaktivnost među tienopiridinima (vidjeti dio 4.8).
Luxembourg/Luxemburg ratiopharm GmbH Tel: +49 731 402 02
Luxembourg/Luxemburg ratiopharm GmbH Allemagne/Deutschland Tél/Tel: +49 731 402 02
If you experience prolonged bleeding when taking Clopidogrel ratiopharm.
Ako pri uzimanju Klopidogrela ratiopharm imate produljeno krvarenje
Tablet core:
Veličine pakiranja:
Magyarország Teva Magyarország Zrt.
Teva Gyógyszergyár Zrt.
Slovenská republika TEVA Pharmaceuticals Slovakia s.r.o.
Teva Pharmaceuticals CR, s.r.o.
Medicinal products that inhibit CYP2C19 include omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine, oxcarbazepine and chloramphenicol.
Lijekovi koji su jaki ili umjereni inhibitori CYP2C19 uključuju, primjerice, omeprazol i esomeprazol, fluvoksamin, fluoksetin, moklobemid, vorikonazol, flukonazol, tiklopidin, karbamazepin i efavirenz.
You should not breastfeed while taking this medicine.
Dok uzimate ovaj lijek, ne biste smjeli dojiti.
Patients should be told that it might take longer than usual to stop bleeding when they take clopidogrel, and that they should report any unusual bleeding (site or duration) to their physician.
Bolesnicima koji uzimaju klopidogrel (kao monoterapiju ili u kombinaciji s ASK) potrebno je objasniti da će krvarenje možda trajati dulje nego obično i da moraju obavijestiti liječnika o svakom neočekivanom krvarenju (s obzirom na mjesto i trajanje krvarenja).
The pharmacokinetics of the active metabolite of clopidogrel is not known in these special
Farmakokinetika aktivnog metabolita klopidogrela nije poznata za sljedeće posebne skupine bolesnika.
Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation.
Mehanizam djelovanja Klopidogrel je predlijek, čiji je jedan metabolit inhibitor agregacije trombocita.
If you suffer from severe liver disease;
• ako imate bolest bubrega ili jetre
The recommended dose is one 75 mg tablet of Clopidogrel ratiopharm per day to be taken orally with or without food, and at the same time each day.
Preporučena doza, uključujući za bolesnike sa stanjem zvanim „fibrilacija atrija“ (nepravilni otkucaji srca), je jedna tableta Klopidogrel ratiopharma od 75 mg dnevno koja se uzima kroz usta, s obrokom ili bez obroka, i u isto vrijeme svaki dan.
In vitro, this metabolic pathway is mediated by CYP3A4, CYP2C19, CYP1A2 and CYP2B6.
Aktivni metabolit nastaje većinom putem CYP2C19 uz sudjelovanje nekoliko drugih CYP enzima, uključujući CYP1A2, CYP2B6 i CYP3A4.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically
Međutim, bolesnici koji su sudjelovali u kliničkim ispitivanjima s klopidogrelom istodobno su primali niz lijekova, među kojima su bili diuretici, beta blokatori, ACE inhibitori, antagonisti kalcija, lijekovi za snižavanje kolesterola, koronarni vazodilatatori, antidijabetici (uključujući inzulin), antiepileptici te antagonisti glikoproteina IIb/IIIa bez znakova klinički značajnih štetnih interakcija.
Therapeutic experience is limited in patients with renal impairment (see section 4.4).
Terapijsko iskustvo u bolesnika s narušenom funkcijom bubrega je ograničeno (vidjeti dio 4.4.).
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or
Manje izraženo smanjenje izloženosti aktivnom metabolitu klopidogrela opaženo je kod pantoprazola i lanzoprazola.